DexCom (DXCM) Stock Forecast & Price Target

Q: What analysts cover DexCom?

DexCom has been rated by research analysts at Argus , Barclays , Benchmark , BTIG Research , Canaccord Genuity Group , Citigroup , JPMorgan Chase & Co. , Mizuho , Piper Sandler , Raymond James Financial , Robert W. Baird , Royal Bank Of Canada , Stifel Nicolaus , TD Cowen , Truist Financial , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$84.11 -0.30 (-0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$84.06 -0.05 (-0.05%)

As of 07:30 PM Eastern

Compare

DexCom - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Buy

Based on 24 Analyst Ratings

Sell
0

Hold
2

Buy
22

Based on 24 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Buy." Out of the 24 analysts, 2 have given a hold rating, 19 have given a buy rating, and 3 have given a strong buy rating for DXCM.

Consensus Price Target

$91.96
9.33% Upside

According to the 24 analysts' twelve-month price targets for DexCom, the average price target is $91.96. The highest price target for DXCM is $115.00, while the lowest price target for DXCM is $75.00. The average price target represents a forecasted upside of 9.33% from the current price of $84.11.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXCM Analyst Ratings Over Time

Type	Current Forecast 10/9/25 to 10/9/26	1 Month Ago 9/9/25 to 9/9/26	3 Months Ago 7/11/25 to 7/11/26	1 Year Ago 10/9/24 to 10/9/25
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	19 Buy rating(s)	21 Buy rating(s)	21 Buy rating(s)	14 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$91.96	$88.71	$84.88	$97.42
Forecasted Upside	9.33% Upside	5.76% Upside	13.23% Upside	43.10% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Healthcare Companies	Broader Market
Consensus Rating Score	3.04	2.32	2.52
Consensus Rating	Buy	Hold	Moderate Buy
Predicted Upside	9.65% Upside	920.34% Upside	19.54% Upside
News Sentiment Rating	Positive News See Recent DXCM News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/7/2026	Barclays 3 of 5 stars	Christopher Pasquale Not Rated	Upgrade	Strong-Buy
10/6/2026	Weiss Ratings 3 of 5 stars		Upgrade	Hold (C) ➝ Hold (C+)
10/1/2026	Royal Bank Of Canada 3 of 5 stars	Kendall Au Not Rated	Reiterated Rating	Outperform	$90.00 ➝ $105.00	+21.68%
9/18/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$93.00 ➝ $102.00	+15.26%
9/18/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$95.00	+7.35%
8/4/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Silver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$86.00 ➝ $96.00	+11.08%
8/3/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$82.00 ➝ $90.00	+3.60%
7/31/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Strong-Buy	$94.00	+11.54%
7/31/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$88.00 ➝ $95.00	+27.45%
7/31/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$105.00	+24.59%
Get the Latest News and Ratings for DXCM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.
7/31/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$84.00 ➝ $88.00	+18.06%
7/31/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$80.00 ➝ $90.00	+20.74%
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$90.00 ➝ $95.00	+27.45%
7/31/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$90.00 ➝ $95.00	+14.08%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$65.00 ➝ $82.00	-1.32%
7/31/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$85.00 ➝ $90.00	+10.34%
7/31/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Jackson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$77.00 ➝ $82.00	-0.33%
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$96.00	+26.92%
6/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kieran Ryan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$86.00	+24.51%
5/18/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$100.00 ➝ $80.00	+24.53%
5/15/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$77.00	+25.35%
3/24/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$90.00	+36.49%
1/12/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight
12/16/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$92.00	+39.97%
10/1/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kate McShane Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$104.00 ➝ $89.00	+37.98%
9/8/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Lichtman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	T. Perez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
2/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Issie Kirby Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$85.00 ➝ $115.00	+32.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:13 PM ET.

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 5, 2026. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

DexCom, Inc. recently reported strong financial performance for the quarter ended July 30, 2026, with earnings per share of $0.70, which beat the analyst consensus estimate of $0.61 by $0.09, and revenue of $1.31 billion, exceeding the expected $1.29 billion, demonstrating the company's ability to outperform market expectations and drive shareholder value.
The company's stock is currently trading at $86.90, which is below the average analyst price target of $89.74, suggesting potential upside for investors as the consensus rating remains a "Moderate Buy" with 21 analysts issuing Buy ratings and only one Sell rating, indicating broad institutional confidence in the stock's future growth.
DexCom, Inc. is expanding its market reach by becoming the official continuous glucose monitor for Team Novo Nordisk, a partnership that leverages the global visibility of the diabetes care brand to increase adoption of its Dexcom G7 and Dexcom G6 systems, potentially driving higher sales volumes and brand loyalty in the competitive CGM market.
The company has demonstrated consistent year-over-year revenue growth, with the most recent quarter showing a 13.1% increase compared to the same period last year, and the prior quarter showing 15.0% growth, indicating a robust and accelerating demand for its continuous glucose monitoring technology among people with diabetes and healthcare providers.
Institutional investor interest in DexCom, Inc. has been strong, with 97.75% of the company's stock owned by institutional investors and hedge funds, and recent new positions acquired by firms such as Bright Rock Capital Management LLC and Mitsubishi UFJ Asset Management Co. Ltd., signaling that sophisticated investors are confident in the company's long-term strategic position in the healthcare equipment sector.

DexCom
Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

Insider selling activity has been significant in recent months, with executives and directors such as Sadie Stern, Nicholas Augustinos, and Jereme Sylvain selling a combined total of over 16,000 shares in September 2026 alone, and insiders collectively selling 49,313 shares worth approximately $3.9 million in the last 90 days, which may signal a lack of confidence from those with the most intimate knowledge of the company's operations.
The company's stock has a beta of 1.48, indicating that it is more volatile than the overall market, and its price has fluctuated significantly within its 52-week range of $54.11 to $92.59, exposing investors to higher risk of price swings that may not be suitable for those with a lower risk tolerance.
Short interest in DexCom, Inc. has been relatively high, with 17,263,625 shares shorted as of September 15, 2026, representing approximately 4.59% of the float, and a days-to-cover ratio of 4.98, suggesting that a significant portion of the market is betting against the stock's future performance, which could lead to further downward pressure on the share price.
The company's P/E ratio of 33.47 is relatively high compared to the broader market, indicating that investors are paying a premium for its earnings, and any future disappointment in earnings growth or revenue performance could lead to a significant re-rating of the stock, as the market may no longer justify the current valuation multiple.
DexCom, Inc. faces increasing competition in the continuous glucose monitoring market, with new entrants such as Oura, which is preparing for a $15.6 billion IPO, and established players like Abbott Laboratories, which may erode DexCom's market share and pricing power, particularly as the market becomes more saturated and price-sensitive.

DXCM Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $91.96, with a high forecast of $115.00 and a low forecast of $75.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXCM shares.

According to analysts, DexCom's stock has a predicted upside of 9.33% based on their 12-month stock forecasts.

Over the previous 90 days, DexCom's stock had 3 upgrades and 1 downgrade by analysts.

DexCom has been rated by research analysts at Argus, Barclays, Benchmark, BTIG Research, Canaccord Genuity Group, Citigroup, JPMorgan Chase & Co., Mizuho, Piper Sandler, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like DexCom more than other "healthcare" companies. The consensus rating for DexCom is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how DXCM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With DexCom Recommendations

MarketBeat monitors more than a dozen sources for DexCom analyst ratings, with the most recent rating issued on 10/7/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Stock Forecast & Price Target